JP2023523211A5 - - Google Patents
Info
- Publication number
- JP2023523211A5 JP2023523211A5 JP2022563882A JP2022563882A JP2023523211A5 JP 2023523211 A5 JP2023523211 A5 JP 2023523211A5 JP 2022563882 A JP2022563882 A JP 2022563882A JP 2022563882 A JP2022563882 A JP 2022563882A JP 2023523211 A5 JP2023523211 A5 JP 2023523211A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- transgene
- retinal
- peptide
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20315217.8 | 2020-04-24 | ||
| EP20315217 | 2020-04-24 | ||
| EP20305407.7 | 2020-04-27 | ||
| EP20305407 | 2020-04-27 | ||
| PCT/EP2021/060647 WO2021214282A1 (en) | 2020-04-24 | 2021-04-23 | Methods for preventing induction of immune responses to the transduced cells expressing a transgene product after ocular gene therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023523211A JP2023523211A (ja) | 2023-06-02 |
| JP2023523211A5 true JP2023523211A5 (enExample) | 2024-02-08 |
Family
ID=75625591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563882A Pending JP2023523211A (ja) | 2020-04-24 | 2021-04-23 | 眼科遺伝子治療後の、導入遺伝子産物を発現する形質転換細胞に対する免疫応答の誘導を防止するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230190956A1 (enExample) |
| EP (1) | EP4138929A1 (enExample) |
| JP (1) | JP2023523211A (enExample) |
| CA (1) | CA3179895A1 (enExample) |
| WO (1) | WO2021214282A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026005189A1 (ko) * | 2024-06-27 | 2026-01-02 | 이엔셀 주식회사 | 안구 세포 또는 조직을 표적하는 펩타이드 및 이를 포함하는 바이러스 캡시드 단백질 및 바이러스 벡터 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639872A (en) | 1993-07-27 | 1997-06-17 | Hybridon, Inc. | Human VEGF-specific oligonucleotides |
| US6306829B1 (en) | 1995-12-08 | 2001-10-23 | Hybridon, Inc. | Modified VEGF oligonucleotides for treatment of skin disorders |
| US20030144221A1 (en) | 2001-07-17 | 2003-07-31 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL2-associated X protein expression |
| PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| ES2423060T3 (es) | 2004-03-12 | 2013-09-17 | Alnylam Pharmaceuticals, Inc. | Agentes iRNA que tienen como diana al VEGF |
| EP1919497B1 (en) | 2005-07-22 | 2020-02-12 | The Board of Trustees of the Leland Stanford Junior University | Light-activated cation channel and uses thereof |
| CN101484005A (zh) | 2006-05-04 | 2009-07-15 | 韦恩州立大学 | 通过向体内递送视紫红质核酸恢复视觉响应 |
| US7872118B2 (en) | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
| US20100081707A1 (en) * | 2008-02-21 | 2010-04-01 | Ali Robin R | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| HK1202434A1 (en) * | 2011-11-22 | 2015-10-02 | The Children's Hospital Of Philadelphia | Virus vectors for highly efficient transgene delivery |
| AU2017257169B2 (en) * | 2016-04-29 | 2021-07-08 | Adverum Biotechnologies, Inc. | Evasion of neutralizing antibodies by a recombinant adeno-associated virus |
-
2021
- 2021-04-23 CA CA3179895A patent/CA3179895A1/en active Pending
- 2021-04-23 WO PCT/EP2021/060647 patent/WO2021214282A1/en not_active Ceased
- 2021-04-23 EP EP21720493.2A patent/EP4138929A1/en not_active Withdrawn
- 2021-04-23 US US17/996,987 patent/US20230190956A1/en active Pending
- 2021-04-23 JP JP2022563882A patent/JP2023523211A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Drag et al. | Gene therapy for retinal degenerative diseases: progress, challenges, and future directions | |
| Seitz et al. | Superior retinal gene transfer and biodistribution profile of subretinal versus intravitreal delivery of AAV8 in nonhuman primates | |
| Ali et al. | Adeno-associated virus gene transfer to mouse retina | |
| JP2022141670A5 (enExample) | ||
| JP2021503914A5 (enExample) | ||
| WO2017070491A1 (en) | Ophthalmic formulations | |
| JP2022522776A5 (enExample) | ||
| JP2025513072A5 (enExample) | ||
| WO2023198050A1 (zh) | 一种融合型腺相关病毒及其应用 | |
| JP2023523211A5 (enExample) | ||
| JP2022533983A5 (enExample) | ||
| JP7624727B2 (ja) | 合理的設計により増強された新規なａａｖウイルスによる網膜における高効率の形質導入および側方への広がり | |
| AU2024287813A1 (en) | Periocular delivery of aav vectors for treating ophthalmic pathologies | |
| JP2022523050A5 (enExample) | ||
| Bennett | Commentary: an aye for eye gene therapy | |
| Alves et al. | AAV-mediated gene therapy for CRB1-hereditary retinopathies | |
| US20230190956A1 (en) | Methods for preventing induction of immune responses to the transduced cells expressing a transgene product after ocular gene therapy | |
| Yoshioka et al. | Recombinant AAV-transduced iris pigment epithelial cell transplantation may transfer vector to native RPE but suppress systemic dissemination | |
| Xie et al. | Sustained and Efficient Delivery of Antivascular Endothelial Growth Factor by the Adeno‐associated Virus for the Treatment of Corneal Neovascularization: An Outlook for Its Clinical Translation | |
| CN111849998A (zh) | 编码人卵黄状黄斑病蛋白1的核酸分子及其应用 | |
| Rudnick et al. | Adeno-associated Viral Vectors in the Retina: Delivering Gene Therapy to the Right Destination | |
| US20050106729A1 (en) | Gene transfer methods and compositions | |
| US20210308169A1 (en) | Methods and compositions for treatment of retinal degenerative diseases | |
| WO2024238853A1 (en) | Adeno-associated viruses for ocular delivery of gene therapy | |
| JP2026503581A (ja) | 新規なカプシドタンパク質バリアント及びその使用 |